Elevar Therapeutics Resubmitted Liver Cancer Drug Application
The company has renewed its request for FDA approval of a combination therapy for advanced liver cancer patients.
Updated on Oct. 14, 2026 in Cancer
Live Poll
Should regulatory bodies prioritize faster access to new cancer drugs despite potential safety uncertainties?
Elevar Therapeutics has resubmitted a New Drug Application to the FDA for a combination therapy consisting of rivoceranib and camrelizumab. This move follows the receipt of a Complete Response Letter from the agency in July 2026.
Why it matters
The company seeks to provide a new first-line systemic treatment option for unresectable or metastatic hepatocellular carcinoma. This submission aims to address significant unmet medical needs for patients facing advanced liver cancer.
The CARES-310 study reported a median overall survival of 23.8 months for the combination therapy compared to 15.2 months for the control group. The study also recorded a hazard ratio for survival outcomes of 0.64.
The players
Elevar Therapeutics
A pharmaceutical company headquartered in Fort Lee, New Jersey, that develops cancer therapies.
FDA
The United States regulatory agency responsible for overseeing the safety and efficacy of new drug applications.
Hengrui Pharma
A pharmaceutical company based in China that collaborated with Elevar Therapeutics on the treatment.
The details
Elevar Therapeutics, a subsidiary of HLB Co., Ltd., collaborated with Hengrui Pharma to prepare the updated application. The treatment is intended for patients diagnosed with unresectable or metastatic hepatocellular carcinoma.
Timeline
January 2026: Initial New Drug Application submitted to FDA.
July 2026: FDA issued a Complete Response Letter.
October 9, 2026: Resubmission of the New Drug Application.
The Big Picture
The Big Picture: This drug submission relies on clinical data established by the CARES-310 study to support its efficacy claims. The research provides the foundational survival metrics necessary for evaluating new systemic treatments in oncology.
This resubmission marks a step forward in potential treatment accessibility for those diagnosed with advanced liver cancer. Future FDA approval could offer patients a new systemic option that has demonstrated improved survival outcomes compared to existing standards.
The takeaway
Advancements in combination therapies continue to play a critical role in treating complex malignancies like hepatocellular carcinoma. Patients and families are encouraged to consult with their oncologists about clinical trial developments and available treatment pathways.
Further reading
For more on ongoing research, visit Cancer.
More information
Review company updates and research progress on the Elevar Therapeutics company information portal.
Live Poll
Should regulatory bodies prioritize faster access to new cancer drugs despite potential safety uncertainties?
